|
|
December 2009
The National Cancer Research Institute established a task force to examine the issues facing researchers engaged in human tissue research. Their report includes proposals to create a clear and practical pathway through the regulatory and governance framework to make human tissues and pathology research more accessible and; a communication programme to promote and create enhanced recognition of the patient benefit arising from such research. For full details see: http://ncri.org.uk
November 2009
The rapid organic growth and commercial potential of newcomer Pathology Diagnostics Ltd. has won it the 2009 ERBI Start-up Award, which is sponsored by the East of England Development Agency. Pathology Diagnostics Ltd. has achieved a six figure turnover without upfront equity investment. It provides a one-stop solution for human tissue diagnostics. Supporting the development of new medicines, it assesses how drugs work on their target tissues from discovery in the lab to clinical trials. ERBI is a not-for-profit membership organisation based in Cambridge, which provides a platform for its member life science and healthcare companies to meet, interact and internationalise their businesses. Founded in 1997, it has become Europe's leading lifescience and healthcare cluster organisation.
Destination Growth is the region's flagship business event for leaders of regional small and medium-sized businesses. Sponsored by EEDA it is the East of England's biggest business and networking event.
October 2009
“This one day event is for managers and scientists involved in the research, development, regulation and business opportunities surrounding devices, diagnostics, biologics, small molecules and other related healthcare and life science therapeutics. Plenary sessions include drug repurposing and regenerative medicine. It is an excellent opportunity to meet new business partners”. For further information please visit: http://www.bench2boardroom.com/ Pathology Diagnostics Ltd. will be present to discuss our services and solutions that meet your key drug and biomarker development issues. To arrange a partnering meeting, please contact: info@pathologydiagnostics.com.
“The success of a company’s drug development programme is increasingly dependent upon the early stage identification of a drug’s true potential (including its limitations) at the drug discovery stage. The aim of this event is to analyse what technologies and strategies are currently being employed in order to both refine and expedite this process, and overcome the various bottlenecks that face the pharmaceutical industry today”. Pathology Diagnostics Ltd. will be present to discuss our services and solutions that meet your key drug and biomarker development issues. To arrange a partnering meeting, please contact: info@pathologydiagnostics.com.
This inaugural world biobanking summit will address topics including: Human Tissue Sample Collection & Storage; Automation; Quality Assurance; Bioethics & Regulations; Harmonization & Standardization.
For full details visit: www.biobanking.com
Pathology Diagnostics Ltd will be attending this event. To arrange a partnering meeting, please contact: info@pathologydiagnostics.com.
June 2009
A study undertaken between Pathology Diagnostics Ltd.; Astra Zeneca, UK; Department of Oncology, Johns Hopkins Medical Center, Baltimore, USA; Centro Integral Oncologica Clara Campal, Madrid, Spain.
Purpose : To determine the efficacy of AZD0530 an orally active small molecule Src inhibitor in human pancreatic xenografts and to seek biomarkers of predictive activity.
For full details visit: http://clincancerres.aacrjournals.org/
ERBI's annual conference is recognised internationally for bringing together hundreds of biotech and medtech executives, showcasing the leading products, services and technologies that are being researched and developed in the Cambridge biotech cluster.
Presentations:
'Immunohistochemistry Markers in Drug Development - Manual versus Automated Scoring’ A collaboration with AstraZeneca UK
“A suite of exploratory IHC biomarkers has been developed to aid decision making in early oncology drug development. The biomarkers are related to the hallmark areas of cancer e.g. apoptosis, proliferation, vascular modulation and invasion. The biomarkers are utilised in clinical trials to assist evaluating biologically effective doses, give insight to proof of mechanism and proof of principle. Formalin-fixed, paraffin embedded sections were stained by IHC. The slides were first scored by eye by a histopathologist according to standard templates and then by a scientist using semi-automated image analysis (Chromavision ACIS II system). Analysis of the histopathologist-scored slides demonstrated associations between markers in similar biological effect areas”.
For full details visit: http://www.path.org.uk/
‘An Impending Crisis in the Provision of Histopathology Expertise for Mouse Functional Genomics’ A collaboration by the EU funded PRIME consortium
“The generation of new mouse models of human disease is accelerating rapidly, due to the completion of whole-genome sequencing efforts and technological advances in the manipulation of the mouse genome. We sought to investigate manpower issues in the provision of histopathology expertise for mouse functional genomics and compared this to the perceived demand from principal investigators (PIs). Through the European Commission (EC)-funded PRIME pathology training initiative, two questionnaires were devised to collect information from pathologists and EC-funded PIs on the current provision of mouse histopathology expertise in Europe and the demands for this service”.
For full details visit: http://www.path.org.uk/
April 2009
The Center for Genomic Pathology (CGP), founded by Robert Cardiff, a distinguished professor of pathology at UC Davis, is a not-for-profit educational foundation whose goal is to collect, integrate and disseminate knowledge about comparative pathology to international academic scientists and pathologists (www.cgp.net). The objective of the CGP is to train the next generation of comparative pathologists their students and staff. The CGP is designed to support educational activities of the Academy of Genomic Pathology (AGP).
March 2009
Madhuri Warren, founder of Pathology Diagnostics Ltd. is interviewed by EEDA in their feature article on women entrepreneurs in the East of England and the Enterprising Women mentoring programme.
Publication date: 18th March 09
For more information visit: www.eeda.org.uk For more on the mentoring programme visit, www.enterprising-women.org/mentors
Febuary 2009
Correspondence article published in Jan 2009 in Nature Biotechnology. This article highlights the increasingly urgent need for trained comparative pathologists, as highlighted by a recent questionnaire survey of pathologists and scientists in Europe, by the EU funded PRIME consortium (Warren, M.V. et al. J. Pathol. 217, 4–13 (2009)).
A forum for delegates from pharmaceutical and biotechnology companies to meet solution providers. Pathology Diagnostics Ltd. will be present to discuss our services and solutions that meet your key business concerns. “The pharmaceutical industry is facing high clinical development costs and declining drug discovery success rates. To stay competitive companies are re-evaluating their drug development process to reduce attrition rates. Biomarkers promise to transform drug discovery, clinical development and molecular diagnostics in the R&D process as effective use of biomarkers at each stage of R&D can improve decision-making, increase clinical trial success rates and productivity”.
January 2009
Research paper published in print January 2009 in the Journal of Pathology (J Pathol. 2009 Jan;217(1):4-13).
The generation of new models of human disease is accelerating rapidly due to the completion of whole-genome sequencing efforts and technological advances. This European Commission (EC)-funded PRIME pathology training initiative study by Warren et al. reveals that histopathological analysis in this field is being performed almost exclusively by highly qualified pathologists in clinical diagnostic posts on a non-contractual basis, often with little support or training in comparative pathology.
The results indicate a lack of both trainees and provision of specialist training in this field, with the availability of diagnostic expertise and advice falling far short of the number of models being generated for analysis. This has lead to the worrying trend of “DIY” pathology and the inaccurate reporting of pathological data in scientific journals. The paper also discusses solutions for the future recruitment, training and funding for pathologists working in functional genomics in Europe.
|
